Tuesday, October 19 2021

VSCompanies touting successful treatment candidates to fight COVID-19 are in the healthcare spotlight, gaining the attention of investors. Experimental treatments are being developed at a rapid pace by many companies of all sizes. This includes biotechnology companies such as iBio (NYSEMKT: IBIO), an innovator specializing in the manufacture and production of antibodies and vaccines under development.

The iBio share price climbed in July of last year after its inclusion in the Russell 2000 and Russell 3000 indices. But soon after, investor confidence weakened due to a lack of news. of its COVID vaccine candidates, resulting in a 75% drop in biotechnology stocks.

Today, a brief resurgence of investor interest is the result of exclusive licensing deals and positive preclinical studies involving its most promising candidates. Could this be a sign of future growth?

Image source: Getty Images.

Candidates who deserve to be supported to find an effective treatment

iBio has four candidates in its current pipeline, three of which focus on human diseases. He is also developing a vaccine to treat animals against swine fever.

All three candidates for human health have reached the preclinical phase of development, while the vaccine for the treatment of animals has progressed a little further in clinical development. Among the most promising candidates is what the company has labeled IBIO-202. It is intended to fight variant strains of the coronavirus by focusing on the neoclapsid (N) protein, which is known to produce a high rate of immune response.

In July, iBio released the results of preclinical studies involving IBIO-202, showing that the focus on the N protein can help produce T cells that help the body fight the virus. The study results support the idea that current vaccines focusing on the spike (S) protein may be effective but may wear off over time, requiring boosters. By focusing on the N protein in combination with the S protein, the vaccine could be more effective and longer lasting.

Cantor Fitzgerald’s Kristen Kluska said, “We believe the company’s approach is sound and could potentially support the ongoing global immunization effort. Cantor currently has a target price of $ 3 on the share, reflecting upside potential of over 170%.

A second candidate in the pipeline that the company is excited about is RTX-003 (renamed IBIO-101), an antibody developed by RubrYc Therapeutics that targets regulatory T cells (Treg) used for immunotherapeutic treatment of cancer. In preclinical studies, it has shown signs of generating strong anti-tumor responses both as monotherapy and in combination with checkpoint inhibitors.

iBio plans to launch an experimental study on a new drug within the next 10 months, with CEO Tom Isett saying the collaboration with RubrYc is a “crucial step for iBio that can create value in many ways.” The company intends to use its proprietary plant-based FastPharming protein expression system, combined with RubrYc’s artificial intelligence platform, to produce additional cancer therapeutic candidates that are safe and scalable. , and at top speeds.

Unique plant-based system leads to expanded capabilities

The FastPharming System is designed for rapid scale-up of vaccines and therapeutics and works by creating a targeted protein through the leaves of iBio’s proprietary plants. As the plants grow, so do the leaves, which are then harvested, and the proteins are separated, cleaned, and made into a final product. By using plants as bioreactors, instead of stainless steel or single-use bioreactors, the system is more in line with green initiatives, and the company maintains that the production method cuts standard processing times by months.

In addition to its pipeline of forward-looking candidates, the company has used the FastPharming system to successfully produce vaccines to fight two variants of influenza. The company has a 130,000 square foot facility with a two-story farm operation that now houses the FastPharming system.

Global exclusive licenses pave the way for a more robust pipeline

At the end of August, iBio disbursed $ 5 million to sign an exclusive worldwide license agreement with RubrYc, which will allow it to continue the development and commercialization of IBIO-101, as well as to have the option of four new molecules developed. with the artificial intelligence of RubrYc. Platform. An additional $ 2.5 million will be paid to RubrYc in December. As part of the deal, iBio also took a stake in the private company.

This agreement follows an exclusive licensing agreement signed with Planet Biotechnology last year, giving iBio the rights to Planet ACE2-Fc’s therapeutic candidate. It is the foundational candidate that iBio is using as part of its current pipeline to develop treatments for the SARS-CoV-2 virus in its efforts to combat COVID variants.

New hype does not justify an investment

The intrigue of investing early in a biopharmaceutical company under the radar is alluring. But with the early stages of a therapeutic pipeline, there is the risk of lower income, higher expenses, and reliance on non-financial news to generate interest.

During the quarter ended June 30, all of these characteristics were visible. Revenue for the quarter was down more than 50% from the same period last year, and it was also down 37% from the previous quarter.

Spending has also increased. Research and development expenses climbed 177% to $ 10 million for the full year, due to higher spending to support its pipeline and platform technology. Selling, general and administrative expenses also jumped in the quarter, doubling from the same period a year ago.

The company expects these expenses to continue to grow through 2022, but more slowly than in 2021. Meanwhile, losses continue to add to more than $ 23 million for the year, or a 41% increase from 2020. The company has $ 97 million in cash and cash equivalents, but noted that the current cash position will run out in the first calendar quarter of 2023.

For the bargain hunter investor who doesn’t mind taking risks, a $ 1 share in a company that builds a pipeline to treat infectious and deadly diseases could be a big winner in five to 10 years. It could also be nonexistent if the money runs out. For those looking for more solid ground, there are probably better options.

10 actions we prefer over iBio
When our award-winning team of analysts have stock advice, it can pay off to listen. After all, the newsletter they’ve been running for over a decade, Motley Fool Equity Advisor, has tripled the market. *

They have just revealed what they believe to be the ten best stocks that investors are buying now … and iBio was not one of them! That’s right – they think these 10 stocks are even better buys.

See the 10 actions

* The portfolio advisor returns on September 17, 2021

Jeff Petit has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

Previous

U.S. pharmaceutical company Merck to seek approval for world's first oral antiviral drug for COVID-19 soon

Next

pharma: Mumbai: a pharmaceutical company authorized the cost of the workshop in France for the doctors as a tax deduction | Bombay News

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also